Quarterly Activities/Appendix 4C Cash Flow Report

Melbourne, Australia – 30 January 2026: Percheron Therapeutics Limited (ASX: PER) (‘the Company’), an international biotechnology company focused on the development of novel therapies for oncology and rare diseases, is pleased to provide an update on the Company’s continuing progress during the quarter ended 31 December 2025. Key Points • Final data presented from completed phase I clinical trial